A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, double-dummy,placebo parallel controlled,
multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or
without anlotinib compared with placebo as consolidation treatment in subjects with locally
advanced/unresectable (Stage III) Non-Small Cell Lung Cancer that has not progressed after
prior concurrent/sequential chemoradiotherapy.